Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
07 Jan 2023
Historique:
entrez: 19 1 2023
pubmed: 20 1 2023
medline: 20 1 2023
Statut: epublish

Résumé

As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine. Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We then investigated the kinetics of responses to these regions in those with varying severity of acute COVID-19. We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, with WT infected individuals predominantly recognizing aa155 to 178 regions, delta infected individuals and vaccinated+omicron infected individuals predominantly recognizing regions aa 29 to 52 and aa 274 to 294 regions. Sinopharm vaccinees recognized all four regions, with the magnitude of responses significantly lower than other groups. >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses. N-protein specific responses appear to be detectable in over 90% of those who were naturally infected or vaccinated with a whole virus inactivated vaccine, with responses mainly directed against four regions of the protein, which were highly conserved. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.

Sections du résumé

Background UNASSIGNED
As there are limited data on B cell epitopes for the nucleocapsid protein in SARS-CoV-2, we sought to identify the immunodominant regions within the N protein, recognized by patients with varying severity of natural infection with the Wuhan strain (WT), delta, omicron and in those who received the Sinopharm vaccines, which is an inactivated, whole virus vaccine.
Methods UNASSIGNED
Using overlapping peptides representing the N protein, with an in-house ELISA, we mapped the immunodominant regions within the N protein, in seronegative (n=30), WT infected (n=30), delta infected (n=30), omicron infected+vaccinated (n=20) and Sinopharm (BBIBP-CorV) vaccinees (n=30). We then investigated the sensitivity and specificity of these immunodominant regions and analysed their conservation with other SARS-CoV-2 variants of concern, seasonal human coronaviruses and bat Sarbecoviruses. We then investigated the kinetics of responses to these regions in those with varying severity of acute COVID-19.
Results UNASSIGNED
We identified four immunodominant regions aa 29-52, aa 155-178, aa 274 to 297 and aa 365 to 388, were highly conserved within SARS-CoV-2 and the bat coronaviruses. The magnitude of responses to these regions varied based on the infecting SARS-CoV-2 variants, with WT infected individuals predominantly recognizing aa155 to 178 regions, delta infected individuals and vaccinated+omicron infected individuals predominantly recognizing regions aa 29 to 52 and aa 274 to 294 regions. Sinopharm vaccinees recognized all four regions, with the magnitude of responses significantly lower than other groups. >80% of individuals gave responses above the positive cut-off threshold to many of the four regions, with some differences with individuals who were infected with different VoCs. These regions were found to be 100% specific, as none of the seronegative individuals gave any responses.
Conclusions UNASSIGNED
N-protein specific responses appear to be detectable in over 90% of those who were naturally infected or vaccinated with a whole virus inactivated vaccine, with responses mainly directed against four regions of the protein, which were highly conserved. As these regions were highly specific with high sensitivity, they have a potential to be used to develop diagnostic assays and to be used in development of vaccines.

Identifiants

pubmed: 36656781
doi: 10.1101/2023.01.05.23284247
pmc: PMC9844014
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI151788
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

PLoS One. 2022 Apr 4;17(4):e0265220
pubmed: 35377884
Trends Immunol. 2022 Mar;43(3):170-172
pubmed: 35125310
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Virus Evol. 2020 Nov 10;6(2):veaa082
pubmed: 33335743
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Lancet Infect Dis. 2022 Sep;22(9):1293-1302
pubmed: 35753318
Nat Immunol. 2022 Jan;23(1):50-61
pubmed: 34853448
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Front Med (Lausanne). 2021 Jan 20;7:607786
pubmed: 33553204
Front Immunol. 2021 Jul 26;12:719037
pubmed: 34381460
Sci Adv. 2022 Aug 5;8(31):eabp9770
pubmed: 35921414
PLoS One. 2021 Nov 8;16(11):e0257548
pubmed: 34748557
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Cell Res. 2022 May;32(5):495-497
pubmed: 35210607
PLoS One. 2022 Jan 13;17(1):e0261142
pubmed: 35025917
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
EBioMedicine. 2022 Jun;80:104062
pubmed: 35594660
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Bioinformatics. 2009 May 1;25(9):1189-91
pubmed: 19151095
N Engl J Med. 2021 Oct 7;385(15):1401-1406
pubmed: 34407341
Immunology. 2022 Oct;167(2):275-285
pubmed: 35758860
Front Public Health. 2022 Jun 21;10:873633
pubmed: 35801250
Sci Rep. 2021 Dec 1;11(1):23216
pubmed: 34853374
Viruses. 2021 Jun 10;13(6):
pubmed: 34200602
Immunology. 2022 Oct;167(2):263-274
pubmed: 35751563
Nat Commun. 2022 Nov 11;13(1):6856
pubmed: 36369151
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Nat Rev Microbiol. 2022 May;20(5):251-252
pubmed: 35288685

Auteurs

Pradeep D Pushpakumara (PD)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Chandima Jeewandara (C)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Farha Bary (F)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Deshan Madushanka (D)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Lahiru Perera (L)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Inoka Sepali Aberathna (IS)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Thashmi Nimasha (T)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Jeewantha Jayamali (J)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Thushali Ranasinghe (T)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Heshan Kuruppu (H)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Saubhagya Danasekara (S)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

Ananda Wijewickrama (A)

National Institute of Infectious Diseases, Angoda, Sri Lanka.

Graham S Ogg (GS)

MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Gathsaurie Neelika Malavige (GN)

Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Classifications MeSH